Fosdenopterin

Chemical structure of cyclic pyranopterin monophosphate

Fosdenopterin is a medication used in the treatment of molybdenum cofactor deficiency (MoCD) Type A, a rare genetic disorder that affects the body's ability to process certain amino acids and other substances. This condition leads to a deficiency in the molybdenum cofactor, which is essential for the activity of several important enzymes.

Mechanism of Action

Fosdenopterin acts as a replacement therapy for cyclic pyranopterin monophosphate (cPMP), a precursor of the molybdenum cofactor. In patients with MoCD Type A, there is a deficiency in the enzyme molybdenum cofactor synthesis step 1 (MOCS1), which is necessary for the production of cPMP. By providing an exogenous source of cPMP, fosdenopterin helps restore the function of molybdenum-dependent enzymes.

Clinical Use

Fosdenopterin is specifically indicated for the treatment of patients with MoCD Type A. This condition is characterized by severe neurological damage, developmental delay, and early mortality if left untreated. The administration of fosdenopterin can help reduce the accumulation of toxic substances in the body and improve clinical outcomes.

Administration

Fosdenopterin is administered intravenously, and the dosage is typically based on the patient's weight. Treatment should be initiated as soon as possible after diagnosis to prevent irreversible neurological damage.

Side Effects

Common side effects of fosdenopterin may include fever, vomiting, and diarrhea. As with any medication, there is also a risk of allergic reactions, which can be serious.

Related Pages

• Molybdenum cofactor deficiency
• Molybdenum cofactor
• Enzyme replacement therapy